Evidence map›Paper›PMID 35999867›Full record

ArticleRenal replacement therapy2022

Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis.

Ayumi Yoshifuji, Masataro Toda, Munekazu Ryuzaki, Kan Kikuchi, Toru Kawai, Ken Sakai, Emi Oyama, Masayoshi Koinuma, Kazuhiko Katayama, Yuki Uehara and 15 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal replacement therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Ayumi Yoshifuji *Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Masataro Toda *Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Munekazu RyuzakiInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Kan KikuchiInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Toru KawaiInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Ken SakaiInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Emi OyamaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Masayoshi KoinumaFaculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
Kazuhiko KatayamaLaboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
Yuki UeharaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Norio OhmagariInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Yoshihiko KannoInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Hirofumi KonInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Toshio ShinodaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Yaoko TakanoInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Junko TanakaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Kazuhiko HoraInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Yasushi NakazawaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Naoki HasegawaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Norio HanafusaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Fumihiko HinoshitaInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Keita MorikaneInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Shu WakinoInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Hidetomo NakamotoInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Yoshiaki TakemotoInfection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo, Japan.
Japanese Society for Dialysis Therapy · JPKitasato University · JPSaiseikai Central Hospital · JPTeikyo Heisei University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Dialysis patients are predisposed to severe disease and have a high mortality rate in coronavirus disease 2019 (COVID-19) due to their comorbidities and immunocompromised conditions. Therefore, dialysis patients should be prioritized for vaccination. This study aimed to examine how long the effects of the vaccine are maintained and what factors affect antibody titers. Methods: Hemodialysis patients (HD group) and age- and sex-matched non-dialysis individuals (Control group), receiving two doses of BNT162b2 vaccine, were recruited through the Japanese Society for Dialysis Therapy (JSDT) Web site in July 2021. Anti-SARS-CoV-2 immunoglobulin (IgG) (SARS-CoV-2 IgG titers) was measured before vaccination, 3 weeks after the first vaccination, 2 weeks after the second vaccination, and 3 months after the second vaccination, and was compared between Control group and HD group. Factors affecting SARS-CoV-2 IgG titers were also examined using multivariable regression analysis and stepwise regression analysis (least AIC). In addition, we compared adverse reactions in Control and HD groups and examined the relationship between adverse reactions and SARS-CoV-2 IgG titers. Results: Our study enrolled 123 participants in the Control group (62.6% men, median age 67.0 years) and 206 patients in the HD group (64.1% men, median age 66.4 years). HD group had significantly lower SARS-CoV-2 IgG titers at 3 weeks after the first vaccination ( Conclusion: HD patients had significantly lower antibody titers than age- and sex-matched non-dialysis individuals over 3 months after vaccination. Dialysis time was identified as a factor affecting SARS-CoV-2 IgG titers in HD group, with longer dialysis time resulting in higher maximum SARS-CoV-2 IgG titers.

Indexed as

Adverse reactionsCOVID-19HemodialysisVaccination

Identifiers

PMID35999867
PMCPMC9388964
OpenAlexW4292337079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.